Daily bars for up to one year, weekly bars for the 5-year view. Averages are 50/200 trading days (10/40 weeks on the 5-year view). Triangles mark past earnings reports, colored by that day’s move; ticks mark ex-dividend dates — hover either for the date. Volume is the shaded bars under the price; switch on RSI or MACD above for a full-history oscillator panel, not just today’s reading.
Reader sentiment, not investment advice. One vote per visitor; click again to change it.
EPOAY last changed hands at $26.46 (up 0.68%). At $31.77B, EPIROC AB UNSPON ADS EACH REP 1 ORD SHS is ranked #645 by size among the 3132 stocks on BeStock.
Over the past 52 weeks it has traded between $19.55 and $30.33, so it sits 12.8% below the top of that range. Holders are ahead 18.4% over twelve months, but down 0.4% across the last three months.
Price is above the 50-day average ($26.45) but below the 200-day ($26.63); RSI is 51, and the last 30 sessions moved at roughly 32% annualized volatility.
Buyers are paying 33.9 times trailing earnings.
This summary is put together from the numbers on the page and updates when they do. It describes the data; it is not a forecast or a recommendation.
Composite of 2 factors below, ranked against the 3132 U.S. stocks BeStock covers.
Higher trailing yield than most of BeStock’s coverage scores higher.
Trading closer to its 52-week high than most peers scores higher.
How this is scored: each factor above is a 0–100 percentile rank against every other stock BeStock covers (or, for Wall Street, against the five-point Strong Buy–Sell scale). The overall grade is the plain average of whichever factors apply to this stock — no factor is weighted more than another. That average maps to a letter: A ≥ 85, B ≥ 70, C ≥ 50, D ≥ 30, otherwise F. Recomputed from the data on this page as prices and filings update — it describes where a stock ranks today, not a forecast, and not a BeStock recommendation to buy or sell.
EPOAY is not currently one of the 10 holdings in BeStock Momentum, our rules-based momentum strategy.
Since 2021-01-04, the strategy has returned 389% (231.1% for the equal-weight average of BeStock’s coverage over the same stretch). Holdings can change any trading day, not just on a fixed schedule. Backtested performance, updated weekly — not a guarantee of future results, and not a BeStock recommendation.
Price return over each window, from adjusted daily and weekly closes
| Indicator | Value | Signal |
|---|---|---|
| Price vs 20-day average | +1.1% | Bullish |
| Price vs 50-day average | +0.1% | Bullish |
| Price vs 200-day average | -0.6% | Bearish |
| 50-day vs 200-day | 50d below 200d | Bearish |
| RSI (14) | 51.1 | Bullish |
| MACD (12,26,9) | -0.13 | Bullish |
| Bollinger band position | 62% | Bullish |
Standard indicator readings worked out from daily closes. They describe how the price has behaved, not where it is going.
Quote as of Oct 5, 2026 10:20 pm ET. Prices can lag the live tape. This is background information, not a recommendation.
Ranks are among the 3,132 or so U.S.-listed stocks BeStock covers, recalculated whenever prices refresh. A tile is left out when the measure does not apply, such as yield for a stock that pays no dividend.
$26.46 is the latest print for EPOAY, a move of +0.68% against yesterday's close of $26.28. Today's low and high so far: $26.10 and $26.56.
Equity value comes to $31.77B at the current price. By that measure it is number 645 of the 3132 names in our coverage.
Buyers pay 33.9 times the last twelve months of profit (EPS $0.78).
The year's floor is $19.55 and the ceiling $30.33. Shares are 12.8% away from that ceiling.
It does. Payouts over the past twelve months work out to a 1.54% yield.
BeStock publishes market data and analysis for information only. Nothing here is investment advice or a solicitation to buy or sell any security, and none of it is tailored to your financial situation, goals, or risk tolerance. Quotes may be delayed and figures can contain errors; check primary sources before you trade. How we source and calculate these pages.
No comments yet — be the first to weigh in on EPOAY.